 |
|
Implications of Marked Weight Gain Associated With Atypical Antipsychotic Medications in Children and Adolescents
Christopher K. Varley, MD;
Jon McClellan, MD
JAMA. 2009;302(16):1811-1812.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The findings reported by Correll and colleagues1 in this issue of JAMA are both timely and sobering. Prior treatment-naive youth (N = 272), aged 4 to 19 years, gained substantial weight during a 12-week period of clinician's choice treatment with atypical antipsychotic medications aripiprazole, olanzapine, quetiapine, or risperidone. The mean weight gain across treatment groups ranged from 8.5 kg with olanzapine to 4.4 kg with aripiprazole. More than half gained more than 7% of their total body weight. Significant abnormalities in lipid profiles and other metabolic parameters were also noted, especially with olanzapine. Comparison patients had minimal changes in body weight and lipid levels over the same period.
These data confirm prior findings that children and adolescents are highly vulnerable to antipsychotic medication–induced weight gain and metabolic adverse effects.2-4 The magnitude of weight gain is particularly concerning, as is the implication that metabolic adverse events . . . [Full Text of this Article]
Author Affiliations: Seattle Children's Hospital, Seattle, Washington (Drs Varley and McClellan); and Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle (Dr McClellan).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
, , , , , and
JAMA. ;302():1765-1773.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
More on Adverse Effects of Antipsychotics on Children
JWatch Psychiatry 2009;2009:1-1.
FULL TEXT
|
